Grant Pickering - Dec 22, 2023 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
Chief Executive Officer, Director
Signature
Grant Pickering, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Dec 22, 2023
Transactions value $
-$905,041
Form type
4
Date filed
12/27/2023, 04:35 PM
Previous filing
Dec 5, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $20.1K +9.9K +2.67% $2.03* 381K Dec 22, 2023 Direct
transaction PCVX Common Stock Options Exercise $400 +10K +2.63% $0.04* 391K Dec 26, 2023 Direct
transaction PCVX Common Stock Sale -$457K -7.45K -1.91% $61.32 383K Dec 26, 2023 Direct F1, F2
transaction PCVX Common Stock Sale -$469K -7.55K -1.97% $62.08 376K Dec 26, 2023 Direct F1, F3
holding PCVX Common Stock 153K Dec 22, 2023 By Children's Trust F4
holding PCVX Common Stock 153K Dec 22, 2023 By Children's Trust F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -9.9K -3.28% $0.00 292K Dec 22, 2023 Common Stock 9.9K $2.03 Direct F6
transaction PCVX Stock Option (right to buy) Options Exercise $0 -10K -73.19% $0.00 3.66K Dec 26, 2023 Common Stock 10K $0.04 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $60.885 to $61.76. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $61.96 to $62.17. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
F5 Shares are held directly by a trust for the benefit of the Reporting Person's son.
F6 Stock Option is fully vested and exercisable.